|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Lucentis inj[樂舒晴 注射劑] information |
|
|
|
製造商 |
Novartis |
|
代理/經銷商 |
Novartis |
|
成份 |
Ranibizumab |
|
適應症 |
Treatment of neovascular (wet) age-related macular degeneration (AMD). |
|
用量 |
0.5 mg (0.05 mL) by intravitreous inj, initiated with a loading phase of 1 inj/mth for 3 consecutive months followed by a maintenance phase in which patients should be monitored for visual acuity on a monthly basis. Interval between 2 doses should not be < 1 month. |
|
過量 |
View Lucentis[樂舒晴] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
Active or suspected ocular or periocular infections, active intraocular inflammation. |
|
注意事項 |
Observe proper aseptic inj technique to avoid infection & inflammation. Monitor intraocular pressure & the perfusion of the optic nerve head. Risk of immunogenicity. May impair ability to drive or operate machinery. Pregnancy & lactation. |
|
不良反應 |
Nasopharyngitis, influenza; anemia; anxiety; headache, stroke; intraocular inflammation, vitritis, vitreous detachment, retinal hemorrhage, visual disturbance, eye pain, vitreous floaters, conjunctival hemorrhage, eye irritation, foreign body sensation in eyes, lacrimation increased, blepharitis, dry eye, ocular hyperemia, eye pruritus; retinal degeneration, retinal disorder, retinal detachment, retinal tear, detachment of retinal pigment epithelium, retinal pigment epithelium tear, visual acuity reduced, vitreous hemorrhage, vitreous disorder, uveitis, iritis, iridacyclitis, cataract, calaract subcapsular, posterior capsule opacification, punctuate keratitis, corneal abrasion, anterior chamber flare, vision blurred, inj site hemorrhage, eye hemorrhage, conjunctivitis, conjunctivitis allergic, eye discharge, photopsia, photophobia, ocular discomfort, eyelid edema, eyelid pain, conjunctival hyperemia; cough; nausea; allergic reactions; arthralgia; intraocular pressure increased.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
[Click for Lucentis[樂舒晴] detailed prescribing infomation]
View more drug interactions with Lucentis[樂舒晴] |
|
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Lucentis[樂舒晴] detailed prescribing infomation |
|
描述 |
View Lucentis[樂舒晴] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Lucentis[樂舒晴] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Lucentis 注射劑 |
|
Lucentis 10 mg/1 mL x 0.23 mL |
|
Lucentis 10 mg/1 mL x 0.3 mL |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Novartis
|
|
|
|
